Skip to content
The Nexus
DossierENTITY

blood cancers

Coverage of blood cancers in the Nexus archive.

Earliest in view: May 27 · 13:00 UTCMost recent: Aug 7 · 03:08 UTC
Co-mentioned in this coverage
Bad Blood 5Ktopic1nonprofitorganization1Capital Regionplace1Siena Universityorganization1Centreorganization1Drugs Rules, 1945topic1cell and gene therapiestopic1stem cell-derived productstopic1regenerative treatmentstopic1CAR-T cell therapiestopic1leukemiastopic1lymphomastopic1National Medical Products Administrationorganization1BeOneorganization1sonrotoclaxtopic1Chinaplace1biotech boomtopic1innovative drugstopic1
Recent coverage
  • HEALTHAug 7 · 03:08 UTCNEWS10 ALBANY
    Bad Blood 5K raises money for nonprofit in Capital Region

    Hundreds of people participated in the Bad Blood 5K on Thursday night, raising money for a nonprofit. This organization supports individuals battling blood cancers within the Capital Region. The event took place on Siena University's campus and included separate loops designed for both runners and walkers.

  • HEALTHJul 2 · 18:04 UTCTHE HINDU NATIONAL
    Centre amends Drugs Rules, 1945 to ensure uniform regulation of advance cell and gene therapies

    The Centre has amended the Drugs Rules, 1945 to establish uniform regulation for advanced cell and gene therapies, including stem cell-based regenerative treatments and CAR-T cell therapies. These therapies are increasingly used to treat blood cancers like leukemias and lymphomas, and the amendment aims to strengthen regulatory oversight of emerging medical technologies.

  • HEALTHMay 27 · 13:00 UTCSCMP WORLD
    China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom

    China’s National Medical Products Administration (NMPA) approved 19 innovative drugs in 2024, with 15 developed by domestic companies, highlighting the country’s biotech growth. Notable approvals include sonrotoclax by BeOne for treating adult blood cancers, as the regulator streamlines its approval process.